D-0926-2017 Class III Terminated

Recalled by Sanofi-Aventis U.S. LLC — Bridgewater, NJ

FDA drug recall D-0926-2017 was initiated by Sanofi-Aventis U.S. LLC on Jun 12, 2017 and is designated Class III. Reason for recall: Superpotent Drug: high out-of-specification result for magnesium. The recall status is terminated (terminated Feb 7, 2019). Affected quantity: 2980 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 5, 2017
Initiation Date
Jun 12, 2017
Termination Date
Feb 7, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2980 bottles

Product description

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Reason for recall

Superpotent Drug: high out-of-specification result for magnesium.

Distribution pattern

Nationwide in the USA, Puerto Rico, and the United Kingdom.

Code information

Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0926-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0926-2017. Report a data issue: hello@regdatalab.com.